NL2017270B1 - New anti-hCTLA-4 antibodies - Google Patents

Info

Publication number

NL2017270B1

NL2017270B1 NL2017270A NL2017270A NL2017270B1 NL 2017270 B1 NL2017270 B1 NL 2017270B1 NL 2017270 A NL2017270 A NL 2017270A NL 2017270 A NL2017270 A NL 2017270A NL 2017270 B1 NL2017270 B1 NL 2017270B1

Authority

NL

Netherlands

Prior art keywords

antibody

antigen

binding fragment

seq

amino acid

Prior art date

2016-08-02

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims abstract description 331
• 238000000034 method Methods 0.000 claims abstract description 122
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 70
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 70
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract description 39
• 239000012634 fragment Substances 0.000 claims description 428
• 239000000427 antigen Substances 0.000 claims description 349
• 108091007433 antigens Proteins 0.000 claims description 348
• 102000036639 antigens Human genes 0.000 claims description 348
• 229940045513 CTLA4 antagonist Drugs 0.000 claims description 164
• 210000004027 cell Anatomy 0.000 claims description 158
• 206010028980 Neoplasm Diseases 0.000 claims description 131
• 201000011510 cancer Diseases 0.000 claims description 117
• 241000282414 Homo sapiens Species 0.000 claims description 83
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 75
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 70
• 102000040430 polynucleotide Human genes 0.000 claims description 64
• 108091033319 polynucleotide Proteins 0.000 claims description 64
• 239000002157 polynucleotide Substances 0.000 claims description 64
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
• 229920001184 polypeptide Polymers 0.000 claims description 61
• -1 LIGHT Proteins 0.000 claims description 58
• 230000014509 gene expression Effects 0.000 claims description 44
• 238000006467 substitution reaction Methods 0.000 claims description 37
• 102000043321 human CTLA4 Human genes 0.000 claims description 34
• 239000003814 drug Substances 0.000 claims description 33
• 239000003112 inhibitor Substances 0.000 claims description 32
• 230000000694 effects Effects 0.000 claims description 31
• 108060003951 Immunoglobulin Proteins 0.000 claims description 30
• 102000018358 immunoglobulin Human genes 0.000 claims description 30
• 239000013604 expression vector Substances 0.000 claims description 29
• 208000015181 infectious disease Diseases 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 28
• 102000004127 Cytokines Human genes 0.000 claims description 21
• 108090000695 Cytokines Proteins 0.000 claims description 21
• 229940124597 therapeutic agent Drugs 0.000 claims description 21
• 150000007523 nucleic acids Chemical class 0.000 claims description 20
• 229960005486 vaccine Drugs 0.000 claims description 19
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 18
• 230000028993 immune response Effects 0.000 claims description 18
• 238000011282 treatment Methods 0.000 claims description 18
• 229960005386 ipilimumab Drugs 0.000 claims description 17
• 201000001441 melanoma Diseases 0.000 claims description 17
• 102000039446 nucleic acids Human genes 0.000 claims description 17
• 108020004707 nucleic acids Proteins 0.000 claims description 17
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 230000035772 mutation Effects 0.000 claims description 16
• 238000001514 detection method Methods 0.000 claims description 15
• 210000002865 immune cell Anatomy 0.000 claims description 14
• 230000001965 increasing effect Effects 0.000 claims description 12
• 238000002560 therapeutic procedure Methods 0.000 claims description 12
• 208000035473 Communicable disease Diseases 0.000 claims description 11
• 229950007217 tremelimumab Drugs 0.000 claims description 11
• 230000000139 costimulatory effect Effects 0.000 claims description 10
• 239000001963 growth medium Substances 0.000 claims description 9
• 102000004889 Interleukin-6 Human genes 0.000 claims description 8
• 108090001005 Interleukin-6 Proteins 0.000 claims description 8
• 241000235648 Pichia Species 0.000 claims description 8
• 238000009169 immunotherapy Methods 0.000 claims description 8
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 7
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 7
• 239000002253 acid Substances 0.000 claims description 7
• 238000012258 culturing Methods 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 229960002621 pembrolizumab Drugs 0.000 claims description 7
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
• 230000000295 complement effect Effects 0.000 claims description 6
• 150000001875 compounds Chemical class 0.000 claims description 6
• 229940127089 cytotoxic agent Drugs 0.000 claims description 6
• 239000003446 ligand Substances 0.000 claims description 6
• 210000000822 natural killer cell Anatomy 0.000 claims description 6
• 229960003301 nivolumab Drugs 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 238000002360 preparation method Methods 0.000 claims description 6
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 206010060862 Prostate cancer Diseases 0.000 claims description 5
• 230000001413 cellular effect Effects 0.000 claims description 5
• 239000002254 cytotoxic agent Substances 0.000 claims description 5
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
• 230000005931 immune cell recruitment Effects 0.000 claims description 5
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 5
• 238000001356 surgical procedure Methods 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 101150013553 CD40 gene Proteins 0.000 claims description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
• 102100025390 Integrin beta-2 Human genes 0.000 claims description 4
• 102000017578 LAG3 Human genes 0.000 claims description 4
• 101150030213 Lag3 gene Proteins 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
• 238000011319 anticancer therapy Methods 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
• 230000002349 favourable effect Effects 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
• 229960001924 melphalan Drugs 0.000 claims description 4
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 239000003381 stabilizer Substances 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
• 102100027207 CD27 antigen Human genes 0.000 claims description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
• 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
• 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 3
• 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
• 206010038389 Renal cancer Diseases 0.000 claims description 3
• 102100029198 SLAM family member 7 Human genes 0.000 claims description 3
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
• 239000012190 activator Substances 0.000 claims description 3
• 239000000556 agonist Substances 0.000 claims description 3
• 229940124675 anti-cancer drug Drugs 0.000 claims description 3
• 229960004630 chlorambucil Drugs 0.000 claims description 3
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
• 229960004316 cisplatin Drugs 0.000 claims description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
• 229960004397 cyclophosphamide Drugs 0.000 claims description 3
• 229960002204 daratumumab Drugs 0.000 claims description 3
• 229960003957 dexamethasone Drugs 0.000 claims description 3
• 229960004679 doxorubicin Drugs 0.000 claims description 3
• 229960004137 elotuzumab Drugs 0.000 claims description 3
• 229960005420 etoposide Drugs 0.000 claims description 3
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
• 229960000390 fludarabine Drugs 0.000 claims description 3
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
• 229940126546 immune checkpoint molecule Drugs 0.000 claims description 3
• 201000010982 kidney cancer Diseases 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 229940046231 pamidronate Drugs 0.000 claims description 3
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
• 229960004641 rituximab Drugs 0.000 claims description 3
• 230000004936 stimulating effect Effects 0.000 claims description 3
• 229960003433 thalidomide Drugs 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 229960004528 vincristine Drugs 0.000 claims description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
• 229940122361 Bisphosphonate Drugs 0.000 claims description 2
• 102100024263 CD160 antigen Human genes 0.000 claims description 2
• 102100038078 CD276 antigen Human genes 0.000 claims description 2
• 102100035793 CD83 antigen Human genes 0.000 claims description 2
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
• 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
• 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 2
• 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 2
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
• 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
• 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 2
• 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
• 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 2
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 2
• 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
• 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
• 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
• 229960000548 alemtuzumab Drugs 0.000 claims description 2
• 229960002707 bendamustine Drugs 0.000 claims description 2
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 2
• 150000004663 bisphosphonates Chemical class 0.000 claims description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
• 239000003246 corticosteroid Substances 0.000 claims description 2
• 229960001334 corticosteroids Drugs 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
• 230000002489 hematologic effect Effects 0.000 claims description 2
• 229960001507 ibrutinib Drugs 0.000 claims description 2
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 2
• IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 claims description 2
• 229940043355 kinase inhibitor Drugs 0.000 claims description 2
• 229960004942 lenalidomide Drugs 0.000 claims description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
• 230000003902 lesion Effects 0.000 claims description 2
• 208000037819 metastatic cancer Diseases 0.000 claims description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
• 229960000688 pomalidomide Drugs 0.000 claims description 2
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
• 229960005205 prednisolone Drugs 0.000 claims description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
• 229950006348 sarilumab Drugs 0.000 claims description 2
• 229950010265 tabalumab Drugs 0.000 claims description 2
• 229960003989 tocilizumab Drugs 0.000 claims description 2
• 239000012646 vaccine adjuvant Substances 0.000 claims description 2
• 229940124931 vaccine adjuvant Drugs 0.000 claims description 2
• 101710185679 CD276 antigen Proteins 0.000 claims 1
• 230000035899 viability Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 abstract description 13
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract description 5
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract description 4
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
• 108090000623 proteins and genes Proteins 0.000 description 76
• 102000004169 proteins and genes Human genes 0.000 description 50
• 235000001014 amino acid Nutrition 0.000 description 49
• 235000018102 proteins Nutrition 0.000 description 47
• 150000001413 amino acids Chemical group 0.000 description 38
• 229940024606 amino acid Drugs 0.000 description 37
• 239000008194 pharmaceutical composition Substances 0.000 description 32
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 28
• 210000001744 T-lymphocyte Anatomy 0.000 description 26
• 241000700605 Viruses Species 0.000 description 26
• 230000006870 function Effects 0.000 description 25
• 230000013595 glycosylation Effects 0.000 description 25
• 238000006206 glycosylation reaction Methods 0.000 description 25
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 24
• 239000012636 effector Substances 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 21
• 238000003556 assay Methods 0.000 description 18
• 239000013598 vector Substances 0.000 description 18
• 108020004414 DNA Proteins 0.000 description 17
• 239000002671 adjuvant Substances 0.000 description 17
• ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 description 17
• 201000010099 disease Diseases 0.000 description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
• 239000012528 membrane Substances 0.000 description 15
• 239000002773 nucleotide Substances 0.000 description 15
• 239000000523 sample Substances 0.000 description 15
• 210000004408 hybridoma Anatomy 0.000 description 14
• 125000003729 nucleotide group Chemical group 0.000 description 14
• 239000002202 Polyethylene glycol Substances 0.000 description 13
• 229920001223 polyethylene glycol Polymers 0.000 description 13
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• 238000002347 injection Methods 0.000 description 12
• 239000007924 injection Substances 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 239000000758 substrate Substances 0.000 description 12
• 230000008685 targeting Effects 0.000 description 12
• 210000004881 tumor cell Anatomy 0.000 description 12
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 11
• 238000013459 approach Methods 0.000 description 11
• 230000000903 blocking effect Effects 0.000 description 11
• 239000003153 chemical reaction reagent Substances 0.000 description 11
• 239000012530 fluid Substances 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 241001529453 unidentified herpesvirus Species 0.000 description 11
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 10
• 108010002350 Interleukin-2 Proteins 0.000 description 10
• 102000000588 Interleukin-2 Human genes 0.000 description 10
• ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 108091026890 Coding region Proteins 0.000 description 9
• 241000588724 Escherichia coli Species 0.000 description 9
• 102000003886 Glycoproteins Human genes 0.000 description 9
• 108090000288 Glycoproteins Proteins 0.000 description 9
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• 210000000612 antigen-presenting cell Anatomy 0.000 description 9
• 230000001580 bacterial effect Effects 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 210000004602 germ cell Anatomy 0.000 description 9
• 238000001802 infusion Methods 0.000 description 9
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 108091008874 T cell receptors Proteins 0.000 description 8
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 239000013612 plasmid Substances 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 239000007790 solid phase Substances 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 108010029485 Protein Isoforms Proteins 0.000 description 7
• 102000001708 Protein Isoforms Human genes 0.000 description 7
• 102000025171 antigen binding proteins Human genes 0.000 description 7
• 108091000831 antigen binding proteins Proteins 0.000 description 7
• WYUKJASPBYYQRJ-VSJOFRJTSA-N beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 WYUKJASPBYYQRJ-VSJOFRJTSA-N 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 108020001507 fusion proteins Proteins 0.000 description 7
• 102000037865 fusion proteins Human genes 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 238000001959 radiotherapy Methods 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 241000701161 unidentified adenovirus Species 0.000 description 7
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• 108010087819 Fc receptors Proteins 0.000 description 6
• 102000009109 Fc receptors Human genes 0.000 description 6
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 6
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 6
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 6
• 102000003816 Interleukin-13 Human genes 0.000 description 6
• 108090000176 Interleukin-13 Proteins 0.000 description 6
• 108010002616 Interleukin-5 Proteins 0.000 description 6
• 102100039897 Interleukin-5 Human genes 0.000 description 6
• 108090001007 Interleukin-8 Proteins 0.000 description 6
• 102000004890 Interleukin-8 Human genes 0.000 description 6
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 6
• 230000006044 T cell activation Effects 0.000 description 6
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
• 108700012920 TNF Proteins 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 235000009582 asparagine Nutrition 0.000 description 6
• 229960001230 asparagine Drugs 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 206010022000 influenza Diseases 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 5
• 108010055166 Chemokine CCL5 Proteins 0.000 description 5
• 239000004971 Cross linker Substances 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 108050003558 Interleukin-17 Proteins 0.000 description 5
• 102000013691 Interleukin-17 Human genes 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 230000006240 deamidation Effects 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 239000011521 glass Substances 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 230000005847 immunogenicity Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 230000000770 proinflammatory effect Effects 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 241000712461 unidentified influenza virus Species 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 4
• SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 4
• 241000759568 Corixa Species 0.000 description 4
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 4
• 241000988559 Enterovirus A Species 0.000 description 4
• 241000991587 Enterovirus C Species 0.000 description 4
• 241000233866 Fungi Species 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 102100021453 Histone deacetylase 5 Human genes 0.000 description 4
• 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 4
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
• 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 4
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
• 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 4
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 4
• 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 4
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
• 102100031413 L-dopachrome tautomerase Human genes 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 241000725643 Respiratory syncytial virus Species 0.000 description 4
• 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 4
• 241000700618 Vaccinia virus Species 0.000 description 4
• 238000011374 additional therapy Methods 0.000 description 4
• 230000005809 anti-tumor immunity Effects 0.000 description 4
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 230000001268 conjugating effect Effects 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 206010014599 encephalitis Diseases 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 102000054189 human CD80 Human genes 0.000 description 4
• 102000049849 human CD86 Human genes 0.000 description 4
• 238000003384 imaging method Methods 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• 230000001717 pathogenic effect Effects 0.000 description 4
• 239000004033 plastic Substances 0.000 description 4
• 229920003023 plastic Polymers 0.000 description 4
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
• 102000016914 ras Proteins Human genes 0.000 description 4
• 210000003289 regulatory T cell Anatomy 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 3
• CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 3
• WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 3
• 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 3
• KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical group NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 3
• JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical group OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 208000035143 Bacterial infection Diseases 0.000 description 3
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
• 108010065524 CD52 Antigen Proteins 0.000 description 3
• 108090000538 Caspase-8 Proteins 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 241000711573 Coronaviridae Species 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• 241000206602 Eukaryota Species 0.000 description 3
• 241000589602 Francisella tularensis Species 0.000 description 3
• 102100040578 G antigen 7 Human genes 0.000 description 3
• 102400000921 Gastrin Human genes 0.000 description 3
• 102000005720 Glutathione transferase Human genes 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 3
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
• 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 3
• 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 3
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 102000003814 Interleukin-10 Human genes 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 102000013462 Interleukin-12 Human genes 0.000 description 3
• 108010065805 Interleukin-12 Proteins 0.000 description 3
• 241000701460 JC polyomavirus Species 0.000 description 3
• 241000712890 Junin mammarenavirus Species 0.000 description 3
• 241000235058 Komagataella pastoris Species 0.000 description 3
• 101710093778 L-dopachrome tautomerase Proteins 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 241000186779 Listeria monocytogenes Species 0.000 description 3
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 3
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 3
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• 241000235061 Pichia sp. Species 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 102000014128 RANK Ligand Human genes 0.000 description 3
• 108010025832 RANK Ligand Proteins 0.000 description 3
• 241000711798 Rabies lyssavirus Species 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 3
• 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 230000005867 T cell response Effects 0.000 description 3
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 102100022748 Wilms tumor protein Human genes 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 208000022362 bacterial infectious disease Diseases 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• GRHWEVYJIHXESA-HBHDJDHDSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 GRHWEVYJIHXESA-HBHDJDHDSA-N 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 229910052805 deuterium Inorganic materials 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 101150023212 fut8 gene Proteins 0.000 description 3
• 229930182830 galactose Natural products 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 108020002326 glutamine synthetase Proteins 0.000 description 3
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• HNQXDLYBFNWFEE-VHZSLYHRSA-N n-[(2r,3r,4r,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-5-[(2r,3s,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-1-oxo-4-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] Chemical compound O([C@H]([C@H](C=O)NC(=O)C)[C@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](CO[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1[C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O HNQXDLYBFNWFEE-VHZSLYHRSA-N 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 229950010773 pidilizumab Drugs 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 108010014186 ras Proteins Proteins 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 238000002603 single-photon emission computed tomography Methods 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• ZUQUTHURQVDNKF-CBQIKETKSA-N 1-[(2R,3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound C(C)(=O)[C@@]1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO ZUQUTHURQVDNKF-CBQIKETKSA-N 0.000 description 2
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
• JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 description 2
• AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
• 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
• 206010069754 Acquired gene mutation Diseases 0.000 description 2
• 102100028100 Activating signal cointegrator 1 Human genes 0.000 description 2
• CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 101710145634 Antigen 1 Proteins 0.000 description 2
• GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000702673 Bovine rotavirus Species 0.000 description 2
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
• 108010029697 CD40 Ligand Proteins 0.000 description 2
• 102100032937 CD40 ligand Human genes 0.000 description 2
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
• 241000222122 Candida albicans Species 0.000 description 2
• 102000004091 Caspase-8 Human genes 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
• 241000606153 Chlamydia trachomatis Species 0.000 description 2
• 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 2
• 102100038215 Chromodomain-helicase-DNA-binding protein 7 Human genes 0.000 description 2
• 241001674013 Chrysosporium lucknowense Species 0.000 description 2
• 241000193403 Clostridium Species 0.000 description 2
• 101100532584 Clostridium perfringens (strain 13 / Type A) sspC1 gene Proteins 0.000 description 2
• 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 241000709687 Coxsackievirus Species 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
• 208000001490 Dengue Diseases 0.000 description 2
• 206010012310 Dengue fever Diseases 0.000 description 2
• 241000725619 Dengue virus Species 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 206010014614 Encephalitis western equine Diseases 0.000 description 2
• 241000709661 Enterovirus Species 0.000 description 2
• 208000000832 Equine Encephalomyelitis Diseases 0.000 description 2
• 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 241000877986 Eyach virus Species 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 241001149959 Fusarium sp. Species 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 108010052343 Gastrins Proteins 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• 229940125497 HER2 kinase inhibitor Drugs 0.000 description 2
• 241000606768 Haemophilus influenzae Species 0.000 description 2
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 102000003964 Histone deacetylase Human genes 0.000 description 2
• 108090000353 Histone deacetylase Proteins 0.000 description 2
• 101000649017 Homo sapiens Activating signal cointegrator 1 Proteins 0.000 description 2
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
• 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
• 101000883739 Homo sapiens Chromodomain-helicase-DNA-binding protein 7 Proteins 0.000 description 2
• 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 2
• 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
• 101001008951 Homo sapiens Kinesin-like protein KIF15 Proteins 0.000 description 2
• 101001050567 Homo sapiens Kinesin-like protein KIF2C Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 2
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
• 101001114052 Homo sapiens P antigen family member 4 Proteins 0.000 description 2
• 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101100095550 Homo sapiens SENP7 gene Proteins 0.000 description 2
• 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
• 101000632529 Homo sapiens Shugoshin 1 Proteins 0.000 description 2
• 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 2
• 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
• 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
• 241000701027 Human herpesvirus 6 Species 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 2
• 241000712431 Influenza A virus Species 0.000 description 2
• 102100026720 Interferon beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
• 102100027630 Kinesin-like protein KIF15 Human genes 0.000 description 2
• 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 2
• 241000170280 Kluyveromyces sp. Species 0.000 description 2
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 241001115401 Marburgvirus Species 0.000 description 2
• 241000712079 Measles morbillivirus Species 0.000 description 2
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
• 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 2
• 102100023123 Mucin-16 Human genes 0.000 description 2
• 241000711386 Mumps virus Species 0.000 description 2
• 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 241000221961 Neurospora crassa Species 0.000 description 2
• 102000011931 Nucleoproteins Human genes 0.000 description 2
• 108010061100 Nucleoproteins Proteins 0.000 description 2
• 241000320412 Ogataea angusta Species 0.000 description 2
• 241001489174 Ogataea minuta Species 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 241000150452 Orthohantavirus Species 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 102100023240 P antigen family member 4 Human genes 0.000 description 2
• 238000012879 PET imaging Methods 0.000 description 2
• 239000002033 PVDF binder Substances 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 102100037686 Protein SSX2 Human genes 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
• 241000710799 Rubella virus Species 0.000 description 2
• 101150098865 SSP2 gene Proteins 0.000 description 2
• 241000235088 Saccharomyces sp. Species 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 102100031406 Sentrin-specific protease 7 Human genes 0.000 description 2
• 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
• 241000607768 Shigella Species 0.000 description 2
• 241000607762 Shigella flexneri Species 0.000 description 2
• 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 2
• 102100028402 Shugoshin 1 Human genes 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 241000191940 Staphylococcus Species 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 2
• 101710137500 T7 RNA polymerase Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 2
• 241000499912 Trichoderma reesei Species 0.000 description 2
• LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
• 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 241000607626 Vibrio cholerae Species 0.000 description 2
• 241000710886 West Nile virus Species 0.000 description 2
• 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 2
• 201000005806 Western equine encephalitis Diseases 0.000 description 2
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 108010047495 alanylglycine Proteins 0.000 description 2
• 108010087924 alanylproline Proteins 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 101150078331 ama-1 gene Proteins 0.000 description 2
• 150000001408 amides Chemical group 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 150000001502 aryl halides Chemical class 0.000 description 2
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
• 108010077245 asparaginyl-proline Proteins 0.000 description 2
• 229940090047 auto-injector Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 229960000455 brentuximab vedotin Drugs 0.000 description 2
• 229940095731 candida albicans Drugs 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 210000000234 capsid Anatomy 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 108010021331 carfilzomib Proteins 0.000 description 2
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
• 210000004520 cell wall skeleton Anatomy 0.000 description 2
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 229940038705 chlamydia trachomatis Drugs 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 229950009003 cilengitide Drugs 0.000 description 2
• AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 108010048032 cyclophilin B Proteins 0.000 description 2
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 239000003145 cytotoxic factor Substances 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
• 208000025729 dengue disease Diseases 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
• RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
• 229960000394 droperidol Drugs 0.000 description 2
• 229950006595 edotreotide Drugs 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 229940082789 erbitux Drugs 0.000 description 2
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 238000011347 external beam therapy Methods 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 229940118764 francisella tularensis Drugs 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
• 239000000185 hemagglutinin Substances 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 102000027596 immune receptors Human genes 0.000 description 2
• 108091008915 immune receptors Proteins 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 238000006317 isomerization reaction Methods 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 229940090046 jet injector Drugs 0.000 description 2
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 229960001614 levamisole Drugs 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 210000003936 merozoite Anatomy 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
• 238000000302 molecular modelling Methods 0.000 description 2
• CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229960002340 pentostatin Drugs 0.000 description 2
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229960002087 pertuzumab Drugs 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 2
• 229960002633 ramucirumab Drugs 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 210000005245 right atrium Anatomy 0.000 description 2
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
• 102200072304 rs1057519530 Human genes 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 230000037439 somatic mutation Effects 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 108091008023 transcriptional regulators Proteins 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 229960001612 trastuzumab emtansine Drugs 0.000 description 2
• 229960003688 tropisetron Drugs 0.000 description 2
• UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 2
• 229940030325 tumor cell vaccine Drugs 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 229950005972 urelumab Drugs 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
• 210000002620 vena cava superior Anatomy 0.000 description 2
• 229940118696 vibrio cholerae Drugs 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• KSOVGRCOLZZTPF-QMKUDKLTSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC(C=C1C)=CC=C1N1CCN(C)CC1 KSOVGRCOLZZTPF-QMKUDKLTSA-N 0.000 description 1
• PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• YWTBGJGMTBHQTM-IBGZPJMESA-N (2S)-1-(1H-indol-3-yl)-3-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-2-propanamine Chemical compound C1=CC=C2C(C[C@H](N)COC=3C=NC=C(C=3)C3=CC=C4NN=C(C4=C3)C)=CNC2=C1 YWTBGJGMTBHQTM-IBGZPJMESA-N 0.000 description 1
• SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
• YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
• NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 description 1
• ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
• GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
• KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• SGYJGGKDGBXCNY-QXUYBEEESA-N (3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@@H]2C(=O)N1)=O)(C)C)CCCCC(=O)[C@@H]1CO1 SGYJGGKDGBXCNY-QXUYBEEESA-N 0.000 description 1
• SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
• OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• SQWZFLMPDUSYGV-POHAHGRESA-N (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=N2)C2=C1 SQWZFLMPDUSYGV-POHAHGRESA-N 0.000 description 1
• OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• JNKQAHJZAUFSLB-BAWYVGMJSA-N (8s,9r,11s,13s,14s,17s)-4-chloro-11-[4-[2-(diethylamino)ethoxy]phenyl]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1[C@@H]1[C@@H]2C3=CC=C(O)C(Cl)=C3CC[C@H]2[C@@H]2CC[C@H](O)[C@@]2(C)C1 JNKQAHJZAUFSLB-BAWYVGMJSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
• WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
• WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 1
• SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
• MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
• ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
• KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
• UQBIAGWOJDEOMN-UHFFFAOYSA-N 2-O-(2-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranosyl)-D-mannopyranose Natural products OC1C(O)C(CO)OC(O)C1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 UQBIAGWOJDEOMN-UHFFFAOYSA-N 0.000 description 1
• RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 1
• SNKUSVNHTCUELQ-UHFFFAOYSA-N 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic aci Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=C(O)C=C1 SNKUSVNHTCUELQ-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
• SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 1
• HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
• UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
• ZHJGWYRLJUCMRT-QGZVFWFLSA-N 5-[6-[(4-methyl-1-piperazinyl)methyl]-1-benzimidazolyl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide Chemical compound O([C@H](C)C=1C(=CC=CC=1)C(F)(F)F)C(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-QGZVFWFLSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• OZPFIJIOIVJZMN-SFHVURJKSA-N 6-[(7s)-7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl]-n-methylnaphthalene-2-carboxamide Chemical compound C1=CC2=CC(C(=O)NC)=CC=C2C=C1[C@]1(O)C2=CN=CN2CC1 OZPFIJIOIVJZMN-SFHVURJKSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• UBIYLIJTJQTBNU-DOKXERMVSA-N 6ob452mc0e Chemical compound O.C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UBIYLIJTJQTBNU-DOKXERMVSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• PBCZSGKMGDDXIJ-XMCQDBRXSA-N 7-hydroxystaurosporine Chemical compound N([C@@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@@H]1C[C@@H](NC)[C@@H](OC)[C@@]3(C)O1 PBCZSGKMGDDXIJ-XMCQDBRXSA-N 0.000 description 1
• PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
• CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 1
• 101150094949 APRT gene Proteins 0.000 description 1
• GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 241000235389 Absidia Species 0.000 description 1
• 241000224422 Acanthamoeba Species 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 241000186046 Actinomyces Species 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 229940126638 Akt inhibitor Drugs 0.000 description 1
• XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
• 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 102000000412 Annexin Human genes 0.000 description 1
• 108050008874 Annexin Proteins 0.000 description 1
• 102000004149 Annexin A2 Human genes 0.000 description 1
• 108090000668 Annexin A2 Proteins 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 1
• 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 1
• 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
• 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
• 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
• 241000712891 Arenavirus Species 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
• IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
• DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 240000006439 Aspergillus oryzae Species 0.000 description 1
• 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 241000228257 Aspergillus sp. Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 239000012664 BCL-2-inhibitor Substances 0.000 description 1
• 108091012583 BCL2 Proteins 0.000 description 1
• OLCWFLWEHWLBTO-HSZRJFAPSA-N BMS-214662 Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 description 1
• 241000223848 Babesia microti Species 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• 241001235574 Balantidium Species 0.000 description 1
• 241000151861 Barnettozyma salicaria Species 0.000 description 1
• 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 241000228405 Blastomyces dermatitidis Species 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 102100027305 Box C/D snoRNA protein 1 Human genes 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 1
• 241000722910 Burkholderia mallei Species 0.000 description 1
• 241001136175 Burkholderia pseudomallei Species 0.000 description 1
• 108010037003 Buserelin Proteins 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
• 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
• 108010077333 CAP1-6D Proteins 0.000 description 1
• 102100024210 CD166 antigen Human genes 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 101150108242 CDC27 gene Proteins 0.000 description 1
• LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 101100228469 Caenorhabditis elegans exp-1 gene Proteins 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 239000005461 Canertinib Substances 0.000 description 1
• 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102100026548 Caspase-8 Human genes 0.000 description 1
• 102100038909 Caveolin-2 Human genes 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
• 102000052603 Chaperonins Human genes 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• SGYJGGKDGBXCNY-UHFFFAOYSA-N Chlamydocin Natural products N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(C)(C)NC(=O)C1CCCCCC(=O)C1CO1 SGYJGGKDGBXCNY-UHFFFAOYSA-N 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 101710164760 Chlorotoxin Proteins 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
• 101710117490 Circumsporozoite protein Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 102100031552 Coactosin-like protein Human genes 0.000 description 1
• 101710105549 Coactosin-like protein Proteins 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 241000204955 Colorado tick fever virus Species 0.000 description 1
• 241000702669 Coltivirus Species 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
• 241000700626 Cowpox virus Species 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 241000223935 Cryptosporidium Species 0.000 description 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 238000011238 DNA vaccination Methods 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 108010019673 Darbepoetin alfa Proteins 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 241000710827 Dengue virus 1 Species 0.000 description 1
• 241000710815 Dengue virus 2 Species 0.000 description 1
• 241000710872 Dengue virus 3 Species 0.000 description 1
• 241000710844 Dengue virus 4 Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
• 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
• 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
• 101150016325 EPHA3 gene Proteins 0.000 description 1
• 239000012824 ERK inhibitor Substances 0.000 description 1
• 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
• 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
• 108700038672 Edotreotide Proteins 0.000 description 1
• 241000605314 Ehrlichia Species 0.000 description 1
• 102100031334 Elongation factor 2 Human genes 0.000 description 1
• 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
• 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 102100025654 Endosome-associated-trafficking regulator 1 Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• 241000988556 Enterovirus B Species 0.000 description 1
• 241000991586 Enterovirus D Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• 108010074604 Epoetin Alfa Proteins 0.000 description 1
• 241000121268 Erythroparvovirus Species 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 102100027285 Fanconi anemia group B protein Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
• 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
• 108010029961 Filgrastim Proteins 0.000 description 1
• 241000711950 Filoviridae Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
• 241000223218 Fusarium Species 0.000 description 1
• 241000567178 Fusarium venenatum Species 0.000 description 1
• 102100039717 G antigen 1 Human genes 0.000 description 1
• 102100039712 G antigen 13 Human genes 0.000 description 1
• 102100039699 G antigen 4 Human genes 0.000 description 1
• 102100039698 G antigen 5 Human genes 0.000 description 1
• 101710092267 G antigen 5 Proteins 0.000 description 1
• 102100039713 G antigen 6 Human genes 0.000 description 1
• 101710092269 G antigen 6 Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
• 102100039554 Galectin-8 Human genes 0.000 description 1
• PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 description 1
• 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102000010956 Glypican Human genes 0.000 description 1
• 108050001154 Glypican Proteins 0.000 description 1
• 108050007237 Glypican-3 Proteins 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 101150012162 H-RAS gene Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 108700010013 HMGB1 Proteins 0.000 description 1
• 101150021904 HMGB1 gene Proteins 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 102100037907 High mobility group protein B1 Human genes 0.000 description 1
• WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 1
• MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000937756 Homo sapiens Box C/D snoRNA protein 1 Proteins 0.000 description 1
• 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 1
• 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
• 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
• 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
• 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
• 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 1
• 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
• 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 1
• 101001056455 Homo sapiens Endosome-associated-trafficking regulator 1 Proteins 0.000 description 1
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
• 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
• 101000886150 Homo sapiens G antigen 13 Proteins 0.000 description 1
• 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 1
• 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
• 101000872458 Homo sapiens Huntingtin-interacting protein 1-related protein Proteins 0.000 description 1
• 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
• 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
• 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
• 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
• 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
• 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
• 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
• 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
• 101001036689 Homo sapiens Melanoma-associated antigen B5 Proteins 0.000 description 1
• 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 1
• 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
• 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101001114057 Homo sapiens P antigen family member 1 Proteins 0.000 description 1
• 101001114056 Homo sapiens P antigen family member 2 Proteins 0.000 description 1
• 101001114053 Homo sapiens P antigen family member 3 Proteins 0.000 description 1
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
• 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
• 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 1
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
• 101001077015 Homo sapiens Rab GTPase-activating protein 1-like Proteins 0.000 description 1
• 101001077011 Homo sapiens Rab GTPase-activating protein 1-like, isoform 10 Proteins 0.000 description 1
• 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 1
• 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
• 101000740529 Homo sapiens Serologically defined colon cancer antigen 8 Proteins 0.000 description 1
• 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
• 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
• 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
• 101000835790 Homo sapiens Tudor domain-containing protein 6 Proteins 0.000 description 1
• 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
• 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
• 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
• 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
• 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
• 101000814511 Homo sapiens X antigen family member 2 Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241001207270 Human enterovirus Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 241000702617 Human parvovirus B19 Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 241000712003 Human respirovirus 3 Species 0.000 description 1
• 241000710124 Human rhinovirus A2 Species 0.000 description 1
• 241001099055 Human rhinovirus A39 Species 0.000 description 1
• 241000710120 Human rhinovirus A89 Species 0.000 description 1
• 241000617996 Human rotavirus Species 0.000 description 1
• 241000702690 Human rotavirus A Species 0.000 description 1
• 241000702692 Human rotavirus B Species 0.000 description 1
• 241000702693 Human rotavirus C Species 0.000 description 1
• 241001559187 Human rubulavirus 2 Species 0.000 description 1
• 102100034773 Huntingtin-interacting protein 1-related protein Human genes 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
• GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 108010042653 IgA receptor Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 description 1
• 241001500351 Influenzavirus A Species 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 102000002227 Interferon Type I Human genes 0.000 description 1
• 108010014726 Interferon Type I Proteins 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102100033461 Interleukin-17A Human genes 0.000 description 1
• 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
• 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
• 201000005807 Japanese encephalitis Diseases 0.000 description 1
• 241000710842 Japanese encephalitis virus Species 0.000 description 1
• 101150069255 KLRC1 gene Proteins 0.000 description 1
• 102100034872 Kallikrein-4 Human genes 0.000 description 1
• 102100034867 Kallikrein-7 Human genes 0.000 description 1
• 102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 1
• 101710134365 Kinesin-like protein KIF2A Proteins 0.000 description 1
• 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
• 241000588747 Klebsiella pneumoniae Species 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
• UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
• CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
• 241001245510 Lambia <signal fly> Species 0.000 description 1
• 241000712902 Lassa mammarenavirus Species 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222727 Leishmania donovani Species 0.000 description 1
• 241000589902 Leptospira Species 0.000 description 1
• VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
• 229940124647 MEK inhibitor Drugs 0.000 description 1
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
• 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
• 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
• 241000712898 Machupo mammarenavirus Species 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
• 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
• 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
• 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
• 102100039475 Melanoma-associated antigen B5 Human genes 0.000 description 1
• 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 1
• 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 241001436793 Meru Species 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• 102000003735 Mesothelin Human genes 0.000 description 1
• 108090000015 Mesothelin Proteins 0.000 description 1
• 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
• 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
• 229940119336 Microtubule stabilizer Drugs 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 241000700559 Molluscipoxvirus Species 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 241000700627 Monkeypox virus Species 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 101710159910 Movement protein Proteins 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 102100034263 Mucin-2 Human genes 0.000 description 1
• 108010008705 Mucin-2 Proteins 0.000 description 1
• 241000235395 Mucor Species 0.000 description 1
• 241000235388 Mucorales Species 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000178382 Mycobacterium lepromatosis Species 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 1
• GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 1
• XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• PCNLLVFKBKMRDB-UHFFFAOYSA-N N-ethyl-N-[[2-(1-pentylindol-3-yl)-1,3-thiazol-4-yl]methyl]ethanamine Chemical compound C(C)N(CC=1N=C(SC=1)C1=CN(C2=CC=CC=C12)CCCCC)CC PCNLLVFKBKMRDB-UHFFFAOYSA-N 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
• 241000224438 Naegleria fowleri Species 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 102000005348 Neuraminidase Human genes 0.000 description 1
• 108010006232 Neuraminidase Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
• 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 101710144117 Non-structural protein 4 Proteins 0.000 description 1
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
• 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• 241001452677 Ogataea methanolica Species 0.000 description 1
• 241000489470 Ogataea trehalophila Species 0.000 description 1
• 241000826199 Ogataea wickerhamii Species 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
• 241000984031 Orientia Species 0.000 description 1
• 241000700629 Orthopoxvirus Species 0.000 description 1
• 101710116435 Outer membrane protein Proteins 0.000 description 1
• 102100023220 P antigen family member 2 Human genes 0.000 description 1
• 102100023239 P antigen family member 3 Human genes 0.000 description 1
• TUVCWJQQGGETHL-UHFFFAOYSA-N PI-103 Chemical compound OC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 TUVCWJQQGGETHL-UHFFFAOYSA-N 0.000 description 1
• 239000012828 PI3K inhibitor Substances 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108060006580 PRAME Proteins 0.000 description 1
• 102000036673 PRAME Human genes 0.000 description 1
• 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
• 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
• QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
• 241000700639 Parapoxvirus Species 0.000 description 1
• 241000701945 Parvoviridae Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
• 241000150350 Peribunyaviridae Species 0.000 description 1
• 241000530350 Phaffomyces opuntiae Species 0.000 description 1
• 241000529953 Phaffomyces thermotolerans Species 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
• 108010053210 Phycocyanin Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000195887 Physcomitrella patens Species 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 241000235062 Pichia membranifaciens Species 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 102100026531 Prelamin-A/C Human genes 0.000 description 1
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
• 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 1
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108091008611 Protein Kinase B Proteins 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
• 101710203858 RNA-binding protein Hfq Proteins 0.000 description 1
• 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
• 102100025165 Rab GTPase-activating protein 1-like, isoform 10 Human genes 0.000 description 1
• 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 241000702247 Reoviridae Species 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 206010039019 Rhabdoid tumour of the kidney Diseases 0.000 description 1
• 241000711931 Rhabdoviridae Species 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 241001325459 Rhinovirus B Species 0.000 description 1
• 241000235527 Rhizopus Species 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000606651 Rickettsiales Species 0.000 description 1
• 239000012891 Ringer solution Substances 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000144820 Rotavirus G9 Species 0.000 description 1
• 241000315672 SARS coronavirus Species 0.000 description 1
• 101150036449 SIRPA gene Proteins 0.000 description 1
• 229940044665 STING agonist Drugs 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
• 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 240000003946 Saponaria officinalis Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 description 1
• LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 102100037221 Serologically defined colon cancer antigen 8 Human genes 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
• 208000001203 Smallpox Diseases 0.000 description 1
• 241000509413 Snow Mountain virus Species 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 241001149962 Sporothrix Species 0.000 description 1
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
• 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
• 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 1
• 102100037346 Substance-P receptor Human genes 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 1
• 108700011582 TER 286 Proteins 0.000 description 1
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
• 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
• JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 1
• 241000404000 Tanapox virus Species 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 102100038126 Tenascin Human genes 0.000 description 1
• 108010008125 Tenascin Proteins 0.000 description 1
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
• QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
• 241000711517 Torovirus Species 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
• 229940123468 Transferase inhibitor Drugs 0.000 description 1
• 241000589886 Treponema Species 0.000 description 1
• RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
• 241000223105 Trypanosoma brucei Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 229940122429 Tubulin inhibitor Drugs 0.000 description 1
• 102100026366 Tudor domain-containing protein 6 Human genes 0.000 description 1
• 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• 102100040362 Tumor protein D53 Human genes 0.000 description 1
• 101710190245 Tumor protein D53 Proteins 0.000 description 1
• 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 241001467018 Typhis Species 0.000 description 1
• CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
• 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
• 101710100179 UMP-CMP kinase Proteins 0.000 description 1
• 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• VEPKQEUBKLEPRA-UHFFFAOYSA-N VX-745 Chemical compound FC1=CC(F)=CC=C1SC1=NN2C=NC(=O)C(C=3C(=CC=CC=3Cl)Cl)=C2C=C1 VEPKQEUBKLEPRA-UHFFFAOYSA-N 0.000 description 1
• JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
• 241000870995 Variola Species 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 241000080633 Viriola Species 0.000 description 1
• 241000370136 Wickerhamomyces pijperi Species 0.000 description 1
• 102100039490 X antigen family member 1 Human genes 0.000 description 1
• 102100039492 X antigen family member 2 Human genes 0.000 description 1
• 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
• 241001536558 Yaba monkey tumor virus Species 0.000 description 1
• 241000235015 Yarrowia lipolytica Species 0.000 description 1
• 241000700574 Yatapoxvirus Species 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• 241000607447 Yersinia enterocolitica Species 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
• 244000126002 Ziziphus vulgaris Species 0.000 description 1
• 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
• UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
• 229960004103 abiraterone acetate Drugs 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
• 229950002421 acolbifene Drugs 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 102000035181 adaptor proteins Human genes 0.000 description 1
• 108091005764 adaptor proteins Proteins 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000037006 agalactosis Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 108010070944 alanylhistidine Proteins 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 108010004469 allophycocyanin Proteins 0.000 description 1
• 229940014175 aloxi Drugs 0.000 description 1
• GLEIMNFBCWCWPW-QOTBAUSGSA-N alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 GLEIMNFBCWCWPW-QOTBAUSGSA-N 0.000 description 1
• ORDAZKGHSNRHTD-UHFFFAOYSA-N alpha-Toxicarol Natural products O1C(C)(C)C=CC2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O ORDAZKGHSNRHTD-UHFFFAOYSA-N 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
• 229950010817 alvocidib Drugs 0.000 description 1
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
• 229960001097 amifostine Drugs 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229960002550 amrubicin Drugs 0.000 description 1
• VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001694 anagrelide Drugs 0.000 description 1
• OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 229940044684 anti-microtubule agent Drugs 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940059707 anzemet Drugs 0.000 description 1
• 229960001372 aprepitant Drugs 0.000 description 1
• ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
• 229950005529 arzoxifene Drugs 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 108010047857 aspartylglycine Proteins 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 229940065779 atarax Drugs 0.000 description 1
• 229940072698 ativan Drugs 0.000 description 1
• 229950010993 atrasentan Drugs 0.000 description 1
• MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229940065181 bacillus anthracis Drugs 0.000 description 1
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
• 229950001429 batabulin Drugs 0.000 description 1
• 229960000817 bazedoxifene Drugs 0.000 description 1
• UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
• 229940088007 benadryl Drugs 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 238000013357 binding ELISA Methods 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 238000002725 brachytherapy Methods 0.000 description 1
• 229940074375 burkholderia mallei Drugs 0.000 description 1
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 230000000981 bystander Effects 0.000 description 1
• RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 1
• PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960005084 calcitriol Drugs 0.000 description 1
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
• 235000020964 calcitriol Nutrition 0.000 description 1
• 239000011612 calcitriol Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 239000003560 cancer drug Substances 0.000 description 1
• 229950002826 canertinib Drugs 0.000 description 1
• OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
• 229950000772 canfosfamide Drugs 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 229960002438 carfilzomib Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 description 1
• 229960003778 casopitant Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 229960002412 cediranib Drugs 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229960001602 ceritinib Drugs 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
• QTFFGPOXNNGTGZ-LIFGOUTFSA-N chembl2368924 Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-LIFGOUTFSA-N 0.000 description 1
• UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
• PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 108700023145 chlamydocin Proteins 0.000 description 1
• 229960005534 chlorotoxin Drugs 0.000 description 1
• QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
• 101150036359 clpB gene Proteins 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 229940088505 compazine Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 229960005061 crizotinib Drugs 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960003843 cyproterone Drugs 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229950005259 dacinostat Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229950006418 dactolisib Drugs 0.000 description 1
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
• 229960002482 dalotuzumab Drugs 0.000 description 1
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
• 229950002966 danusertib Drugs 0.000 description 1
• 229960005029 darbepoetin alfa Drugs 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229940026692 decadron Drugs 0.000 description 1
• 230000022811 deglycosylation Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 1
• GSZRULWGAWHHRI-UHFFFAOYSA-N deguelin Natural products O1C=CC(C)(C)C2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O GSZRULWGAWHHRI-UHFFFAOYSA-N 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• 150000008364 diarylpropionitriles Chemical class 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• BMTPVPNVQOYGAP-UHFFFAOYSA-N diethyl 6-methoxy-5,7-dihydroindolo[2,3-b]carbazole-2,10-dicarboxylate Chemical compound N1C2=CC=C(C(=O)OCC)C=C2C2=C1C(OC)=C1NC3=CC=C(C(=O)OCC)C=C3C1=C2 BMTPVPNVQOYGAP-UHFFFAOYSA-N 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
• 229960000520 diphenhydramine Drugs 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• GDLPAGOVHZLZEK-JBUFHSOLSA-L disodium;(4s)-4-amino-5-[[(1s)-1-carboxylato-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoate Chemical compound [Na+].[Na+].C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC([O-])=O)N)C([O-])=O)=CNC2=C1 GDLPAGOVHZLZEK-JBUFHSOLSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 229960003413 dolasetron Drugs 0.000 description 1
• 108010051081 dopachrome isomerase Proteins 0.000 description 1
• 229950005778 dovitinib Drugs 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 229960004242 dronabinol Drugs 0.000 description 1
• 229950009791 durvalumab Drugs 0.000 description 1
• 229950001287 edotecarin Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 229940108890 emend Drugs 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• 229940007078 entamoeba histolytica Drugs 0.000 description 1
• 229960004671 enzalutamide Drugs 0.000 description 1
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
• 229950002189 enzastaurin Drugs 0.000 description 1
• 229950006370 epacadostat Drugs 0.000 description 1
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 229960003388 epoetin alfa Drugs 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 238000002710 external beam radiation therapy Methods 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 229950002846 ficlatuzumab Drugs 0.000 description 1
• 229960004177 filgrastim Drugs 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 108700014844 flt3 ligand Proteins 0.000 description 1
• 229960002011 fludrocortisone Drugs 0.000 description 1
• AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
• ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 210000000285 follicular dendritic cell Anatomy 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 229950003400 galeterone Drugs 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229950009073 gimatecan Drugs 0.000 description 1
• UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108010078144 glutaminyl-glycine Proteins 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 235000003969 glutathione Nutrition 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 229950005277 gossypol Drugs 0.000 description 1
• 229930000755 gossypol Natural products 0.000 description 1
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
• 229960003727 granisetron Drugs 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 229940095895 haldol Drugs 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
• 229940097277 hygromycin b Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 229940027941 immunoglobulin g Drugs 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229940055742 indium-111 Drugs 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000005133 interdigitating dendritic cell Anatomy 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000006662 intracellular pathway Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 230000006338 isoaspartate formation Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 229960005280 isotretinoin Drugs 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• 108010024383 kallikrein 4 Proteins 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 229940000764 kyprolis Drugs 0.000 description 1
• 210000002664 langerhans' cell Anatomy 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• 229960002367 lasofoxifene Drugs 0.000 description 1
• GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 108010057821 leucylproline Proteins 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 229950011263 lirilumab Drugs 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
• 229950001750 lonafarnib Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• 101150074251 lpp gene Proteins 0.000 description 1
• FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
• 229950005239 lucanthone Drugs 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 150000002704 mannoses Chemical class 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229950008959 marimastat Drugs 0.000 description 1
• 229940099262 marinol Drugs 0.000 description 1
• 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229940064748 medrol Drugs 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229960004503 metoclopramide Drugs 0.000 description 1
• 239000010445 mica Substances 0.000 description 1
• 229910052618 mica group Inorganic materials 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
• QTHCAAFKVUWAFI-DJKKODMXSA-N n-[(e)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1/C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-DJKKODMXSA-N 0.000 description 1
• BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• MUTBJZVSRNUIHA-UHFFFAOYSA-N n-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 description 1
• CBAUPWKIZUBNOQ-UHFFFAOYSA-N n-hydroxy-5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carboxamide Chemical compound CN1N=C(C(F)(F)F)C=C1C1=CC=C(C(=O)NO)S1 CBAUPWKIZUBNOQ-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 238000009099 neoadjuvant therapy Methods 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 229950008835 neratinib Drugs 0.000 description 1
• JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
• WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 1
• 229960005163 netupitant Drugs 0.000 description 1
• 229940060155 neuac Drugs 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
• 229950000891 nolatrexed Drugs 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000012633 nuclear imaging Methods 0.000 description 1
• 229960000435 oblimersen Drugs 0.000 description 1
• MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229960005343 ondansetron Drugs 0.000 description 1
• 238000010397 one-hybrid screening Methods 0.000 description 1
• 229950007283 oregovomab Drugs 0.000 description 1
• 229950004023 orteronel Drugs 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960004390 palbociclib Drugs 0.000 description 1
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
• 229960002131 palonosetron Drugs 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
• 229960001373 pegfilgrastim Drugs 0.000 description 1
• 108010044644 pegfilgrastim Proteins 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
• 229950010632 perifosine Drugs 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000002572 peristaltic effect Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 1
• RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229950004941 pictilisib Drugs 0.000 description 1
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229950007124 pipendoxifene Drugs 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 239000003197 protein kinase B inhibitor Substances 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 229910052761 rare earth metal Inorganic materials 0.000 description 1
• 150000002910 rare earth metals Chemical class 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 229940080693 reglan Drugs 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 208000013860 rhabdoid tumor of the kidney Diseases 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229960001302 ridaforolimus Drugs 0.000 description 1
• 229960003452 romidepsin Drugs 0.000 description 1
• 108010091666 romidepsin Proteins 0.000 description 1
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
• 102200006532 rs112445441 Human genes 0.000 description 1
• 102200007380 rs121913528 Human genes 0.000 description 1
• 102200006531 rs121913529 Human genes 0.000 description 1
• 102200006539 rs121913529 Human genes 0.000 description 1
• 102200006538 rs121913530 Human genes 0.000 description 1
• 102200006540 rs121913530 Human genes 0.000 description 1
• 102200006541 rs121913530 Human genes 0.000 description 1
• 102200007373 rs17851045 Human genes 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• 235000002020 sage Nutrition 0.000 description 1
• DWZAJFZEYZIHPO-UHFFFAOYSA-N santin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 DWZAJFZEYZIHPO-UHFFFAOYSA-N 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 229960002530 sargramostim Drugs 0.000 description 1
• 239000013606 secretion vector Substances 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
• 229950000055 seliciclib Drugs 0.000 description 1
• 229950010746 selumetinib Drugs 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• 229950003647 semaxanib Drugs 0.000 description 1
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
• 125000005629 sialic acid group Chemical group 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 101150082315 spas-1 gene Proteins 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 229940068117 sprycel Drugs 0.000 description 1
• 229950001248 squalamine Drugs 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940081616 tafinlar Drugs 0.000 description 1
• 229950004608 talampanel Drugs 0.000 description 1
• 229950008461 talimogene laherparepvec Drugs 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• 229940056501 technetium 99m Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229950007967 tesmilifene Drugs 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
• 150000003573 thiols Chemical group 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229950009158 tipifarnib Drugs 0.000 description 1
• PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
• 230000008427 tissue turnover Effects 0.000 description 1
• 229950005976 tivantinib Drugs 0.000 description 1
• 229960000940 tivozanib Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960004167 toremifene citrate Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 229950000185 tozasertib Drugs 0.000 description 1
• 229960000977 trabectedin Drugs 0.000 description 1
• PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
• 239000003558 transferase inhibitor Substances 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
• 229960000294 triptorelin pamoate Drugs 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
• 108010073969 valyllysine Proteins 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 125000000391 vinyl group Chemical class [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Chemical class 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
• QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 229940049068 xalkori Drugs 0.000 description 1
• 229940074158 xanax Drugs 0.000 description 1
• 229940098232 yersinia enterocolitica Drugs 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 229950009002 zanolimumab Drugs 0.000 description 1
• 229940034727 zelboraf Drugs 0.000 description 1
• 229940072018 zofran Drugs 0.000 description 1
• 229950009819 zotarolimus Drugs 0.000 description 1
• CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
• 229940052129 zykadia Drugs 0.000 description 1